Literature DB >> 7591238

Growth of ovarian-carcinoma cell lines at physiological folate concentration: effect on folate-binding protein expression in vitro and in vivo.

S Miotti1, P Facheris, A Tomassetti, F Bottero, C Bottini, F Ottone, M I Colnaghi, M A Bunni, D G Priest, S Canevari.   

Abstract

Ovarian-carcinoma cell lines (OVCAR3, IGROVI, OVCA432, SW626 and SKOV3), grown in standard medium containing supra-physiological (2.3 microM) folate concentration, display different levels of reactivity with the anti-folate-binding-protein (FBP) monoclonal antibody MOv18, which recognizes the alpha-isoform of the protein. Gel-filtration and absorption experiments indicated that on IGROVI cells this molecule accounts for all folic-acid binding at nanomolar concentrations. The aim of the study was to investigate the effect of extracellular folate levels on cells adapted to grow in medium containing physiological folate concentration (20 nM). By the ternary complex assay, all cell lines showed a marked depletion of intracellular reduced folates, compared with those in standard folate medium. The monitoring of FBP by MOv18 showed on IGROVI cells a transient up-regulation of the protein, whereas on the other cell lines, except SKOV3, no changes were detected. These data suggest that in these cells further over-expression of the molecule cannot generally be induced by lowering the extracellular folate concentration. On SKOV3, Scatchard analysis of 125I-MOv18 binding, as well as the evaluation of total folate binding capacity, showed a 2- to 3-fold stable increase of FBP expression after long-term growth in low-folate medium. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis indicated in these cells a 1.5-fold increase in alpha-FBP mRNA. SKOV3 cells, maintained in vitro in medium containing supraphysiological and physiological (i.e., low-folate) concentrations were injected into nude mice. Weight differences, though not statistically significant, were observed in favour of low-folate-derived tumors. Immunohistochemical and immunochemical analysis of the tumor samples showed that in SKOV3 cells the receptor modulation can also be induced by restoring the physiological folate concentration in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591238     DOI: 10.1002/ijc.2910630316

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  In vitro and in vivo targeting of different folate receptor-positive cancer cell lines with a novel 99mTc-radiofolate tracer.

Authors:  Cristina Müller; P August Schubiger; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-24       Impact factor: 9.236

2.  Folic acid transport via high affinity carrier-mediated system in human retinoblastoma cells.

Authors:  Viral Kansara; Durga Paturi; Shuanghui Luo; Ripal Gaudana; Ashim K Mitra
Journal:  Int J Pharm       Date:  2007-12-23       Impact factor: 5.875

3.  Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.

Authors:  Peter M Smith-Jones; Neeta Pandit-Taskar; Wei Cao; Joseph O'Donoghue; Martin D Philips; Jorge Carrasquillo; Jason A Konner; Lloyd J Old; Steven M Larson
Journal:  Nucl Med Biol       Date:  2008-04       Impact factor: 2.408

4.  Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines.

Authors:  F Ottone; S Miotti; C Bottini; M Bagnoli; P Perego; M I Colnaghi; S Ménard
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Non-Cytotoxic Quantum Dot-Chitosan Nanogel Biosensing Probe for Potential Cancer Targeting Agent.

Authors:  Tyler Maxwell; Tahmina Banu; Edward Price; Jeremy Tharkur; Maria Gabriela Nogueira Campos; Andre Gesquiere; Swadeshmukul Santra
Journal:  Nanomaterials (Basel)       Date:  2015-12-18       Impact factor: 5.076

6.  Loss of heterozygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas.

Authors:  A Viel; L Dall'Agnese; F Simone; V Canzonieri; E Capozzi; M C Visentin; R Valle; M Boiocchi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.